WHO Greenlights Second Dengue Vaccine Amid Rising Cases

Takeda's Qdenga vaccine, recommended for children in high-risk areas, aims to curb the spread of the mosquito-borne disease.

WHO prequalified Takeda's Qdenga, the second dengue vaccine, for use in children aged 6-16.
The vaccine, requiring two doses, protects against all four dengue serotypes.
Qdenga's approval allows UN agencies to procure it for distribution in poorer countries.
Dengue cases have surged, with a 206% increase in the Americas compared to last year.
Climate change and urbanization are contributing to the global rise in dengue cases.